Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma (NCT04429490) | Clinical Trial Compass
CompletedNot Applicable
Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma
France56 participantsStarted 2020-06-12
Plain-language summary
Pancreatic adenocarcinoma represents more than 90% of pancreatic neoplasms. Around 14000 new cases of pancreatic adenocarcinoma are being diagnosed each year in France and about 8.6% in Grand Est region. National incidence has doubled for men and tripled for women between 1982 and 2012. Pancreatic adenocarcinoma is the deadliest digestive cancer, with only 7 to 8% all stages 5-year survival. It will become the second deadliest in Europe, behind bronchopulmonary cancer.
Several risk factors have been identified such as diabetes, tobacco, chronic pancreatitis or obesity. However, a mismatch exists between incidence forecasts and actual risk factors knowledge. Several hypothesis plead for an environnemental cause.
Plant protection products oncogenetic effects are known and have been proved to be responsible for tumors, including haematological malignancies. Its role in pancreatic carcinogenesis is still poorly studied and show heterogeneous results. They do not allow to conclude for causality. Organochlorines is a specific subset of plant protection product that store in lipids during lifetime.
The aim is to study association between organochlorine concentration in adipose tissue with pancreatic adenocarcinoma.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
inclusion criteria :
Cases :
* patients diagnosed with a pancreatic adenocarcinoma, all stages allowed
* undergoing a surgery allowing to take a 10 grams adipose tissue sample
Controls :
* patients without a pancreatic neoplasm on a 6 months old CT scan before inclusion
* undergoing a surgery allowing to take a 10 grams adipose tissue sample
exclusion criteria :
Cases :
* patients diagnosed with a pancreatic adenocarcinoma developed on IPMN or cystadenoma
* patient with a known genetic predisposition increasing pancreatic adenocarcinoma risk
* histopathology proof of a mixed neuroendocrine neoplasm
* no surgery allowing to take a 10 grams adipose tissue sample
Controls :
* patients with a pancreatic neoplasm on a 6 months old CT scan before inclusion
* no surgery allowing to take a 10 grams adipose tissue sample
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.